2 Biotech Stocks That Could Double Your Money

Over the past 10-plus years, biotech stocks have been one of the best areas of the market to unearth hidden gems. Scores of pre-revenue drugmakers have delivered life-changing gains for their early shareholders over this period. Not every small- to mid-cap biotech stock is a proverbial diamond in the rough, however. Most of these equities, in fact, turn out to be duds due to the enormous difficulty of shepherding an experimental drug from the bench to the market.

Which developmental-stage biotech stocks might be an exception to this general trend? The cancer drugmakers Aptose Biosciences (NASDAQ: APTO) and Five Prime Therapeutics (NASDAQ: FPRX), albeit risky, are both wildly undervalued relative to their long-term prospects. Here's why risk-tolerant investors may want to check out these two under-the-radar biopharma stocks soon.

Image source: Getty Images.

Source Fool.com